Tobacco References

  • Armitage AK, Alexander R, Hopkins R, Ward C. 1988. Evaluation of a low to middle tar/medium nicotine cigarette designed to maintain nicotine delivery to the smoker. Psychopharmacology 96: 447-453.
    http://www.ncbi.nlm.nih.gov/pubmed/3149764
  • Becker KM, Rose JE, Albino AP. 2008. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Nicotine Tob Res 10(7):1139-48.
    http://www.ncbi.nlm.nih.gov/pubmed/18629723
  • Benowitz NL, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd. 2007. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev. 16(11):2479-85.
    http://www.ncbi.nlm.nih.gov/pubmed/18006940
  • Benowitz NL, Dains KM, Hall S, Stewart SL, Wilson M, Dempsey D, Jacob P 3rd. 2012. Smoking Behavior and Exposure to Tobacco Toxicants During 6 months of Smoking Progressively Reduced Nicotine Content Cigarettes. Cancer Epidemiol Biomarkers Prev.
    http://www.ncbi.nlm.nih.gov/pubmed/22354905
  • Donny EC, Houtsmuller E, Stitzer ML. 2007. Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. Addiction 102:324-34.
    http://www.ncbi.nlm.nih.gov/pubmed/17222288
  • Eric C. Donny, Ph.D., et. al. 2015.  Randomized Trial of Reduced-Nicotine Standards for Cigarettes. New England Journal of Medicine. 2015; 373: 1340-1349.
    http://www.nejm.org/doi/full/10.1056/NEJMsa1502403
  • Fagerström KO. 1982. Effect of a nicotine-enriched cigarette on nicotine titration, daily cigarette consumption, and levels of carbon monoxide, cotinine, and nicotine. Psychopharmacology 77:164-167.
    http://www.ncbi.nlm.nih.gov/pubmed/6812134
  • Gori GB, Lynch CJ. 1985. Analytical Cigarette Yields as Predictors of Smoke Bioavailability. Regul Toxicol Pharmacol. 5:314-326.
    http://www.ncbi.nlm.nih.gov/pubmed/4059592
  • Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, Carmella SG, Jensen J, Allen SS, Shields PG, Murphy SE, Stepanov I, Hecht SS. 2010. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 105:343-355.
    http://www.ncbi.nlm.nih.gov/pubmed/20078491
  • Kajikawa M, Shoji T, Kato A, Hashimoto T. 2011. Vacuolar-localized berberine bridge enzyme-like proteins are required for a late step of nicotine biosynthesis in tobacco. Plant Physiology Apr;155(4):2010-22.
    http://www.ncbi.nlm.nih.gov/pubmed/21343426
  • Katoh A, Shoji T, Hashimoto T.  2007.  Molecular cloning of N-methylputrescine oxidase from tobacco. Plant Cell Physiol. 48(3):550–554.
    http://www.ncbi.nlm.nih.gov/pubmed/17283012
  • Mendes P, Liang Q, Frost-Pineda K, Munjal S, Walk RA, Roethig HJ. 2009. The Relationship Between Smoking Machine Derived Tar Yields and Biomarkers of Exposure in Adult Cigarette Smokers in the U.S. Regul Toxicol Pharmacol. 55(1):17-27.
    http://www.ncbi.nlm.nih.gov/pubmed/19481578
  • Michael Fiore, M.D., M.P.H., M.B.A., and Timothy Baker, Ph.D. Reduced-Nicotine Cigarettes — A Promising Regulatory Pathway.  New England Journal of Medicine. 2015; 373: 1289-1291.
    http://www.nejm.org/doi/full/10.1056/NEJMp1509510
  • Morton MJ, Laffoon SW. 2008. Cigarette smoke chemistry market maps under Massachusetts Department of Public Health smoking conditions. Regul Toxicol Pharmacol. 51(1):1-30.
    http://www.ncbi.nlm.nih.gov/pubmed/18433960
  • Pankow JF, Watanabe KH, Toccalino PL, Luo W, Austin DF. 2007. Calculated cancer risks for conventional and “potentially reduced exposure product” cigarettes. Cancer Epidemiol Biomarkers Prev. 16(3):584-92.
    http://www.ncbi.nlm.nih.gov/pubmed/17372256
  • Rose JE. 2006. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology 184:274-285.
    http://www.ncbi.nlm.nih.gov/pubmed/16362402
  • Russell MAH. 2000. Public Health and Levels of Nicotine: Should nicotine be minimized or maximized? In: Nicotine and Public Health. Ferrence R, Slade J, Room, R, Pope M, eds., Washington D.C.: American Public Health Association, pp. 265-284.
    Download PDF
  • Todd AT, Liu E, Polvi SL, Pammett RT, Page JE. 2010.  A functional genomics screen identifies diverse transcription factors that regulate alkaloid biosynthesis in Nicotiana benthamiana.  Plant J. May 1;62(4):589-600.
    http://www.ncbi.nlm.nih.gov/pubmed/20202168
  • Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, Laugesen M, Parag V, Whittaker R. 2012. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: a randomized controlled trial. Addiction. March 30. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/22594651
  • Watanabe KH, Djordjevic MV, Stellman SD, Toccalino PL, Austin DF, Pankow JF. 2009. Regul Toxicol Pharmacol. 55(2):123-33.
    http://www.ncbi.nlm.nih.gov/pubmed/19540296
  • Woodman G, Newman SP, Pavia D, Clarke SW. 1987. The separate effects of tar and nicotine on the cigarette smoking manoeuvre. Eur J Respir Dis. 70:316-321.
    http://www.ncbi.nlm.nih.gov/pubmed/3609190
  • Xie J, Song W, Maksymowicz W, Jin W, Cheah K, Chen W, Carnes C, Ke J, Conkling MA. 2004. Biotechnology: A Tool for Reduced Risk Tobacco Products – The Nicotine Experience From Test Tube to Cigarette Pack. Recent Advances in Tobacco Science 30:17-37.

Cannabis References

  • Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68: 515-21.
    http://www.ncbi.nlm.nih.gov/pubmed/17296917
  • Cooper ZD, Comer SD, Haney M. 2013. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology 38: 1984-2.
    http://www.ncbi.nlm.nih.gov/pubmed/23609132
  • Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B. 2012. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 184: 1143-50.
    http://www.ncbi.nlm.nih.gov/pubmed/22586334
  • Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34: 672-80.
    http://www.ncbi.nlm.nih.gov/pubmed/18688212
  • Elsohly MA, Slade D. 2005. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 78: 539-548.
    http://www.ncbi.nlm.nih.gov/pubmed/16199061
  • Gagne SJ, Stout JM, Liu E, Boubakir Z, Clark SM, Page JE. 2012. Identification of olivetolic acid cyclase from Cannabis sativa reveals a unique catalytic route to plant polyketides. Proc Natl Acad Sci U S A. 109: 12811-6.
    http://www.ncbi.nlm.nih.gov/pubmed/22802619
  • Gaoni Y, Mechoulam R. 1964. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
    http://pubs.acs.org/doi/abs/10.1021/ja01062a046
  • Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. 2007. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 45: 545-54.
    http://www.ncbi.nlm.nih.gov/pubmed/17589370
  • Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. 2009. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-27.
    http://www.ncbi.nlm.nih.gov/pubmed/19729208
  • Joy JE, Watson SJ, Benson JA, eds. 1999. Marijuana and medicine: Assessing the science base. 288 pages.
    http://www.nap.edu/openbook.php?record_id=6376
  • Mechoulam R. 2005. Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol 146: 913-915.
    http://www.ncbi.nlm.nih.gov/pubmed/162057
  • Meijer EPM De, Bagatta M, Carboni A, Crucitti P, Moliterni VMC, Ranalli P, Mandolino G. 2003. The inheritance of chemical phenotype in Cannabis sativa L . Genetcis 346: 335-346.
    http://www.ncbi.nlm.nih.gov/pubmed/12586720
  • Pertwee RG. 2008. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
    http://www.ncbi.nlm.nih.gov/pubmed/17828291
  • Russo EB. 2011. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344-64.
    http://www.ncbi.nlm.nih.gov/pubmed/21749363
  • Sirikantaramas S, Morimoto S, Shoyama Y, Ishikawa Y, Wada Y, Shoyama Y, Taura F. 2004. The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Delta1-tetrahydrocannabinolic acid synthase from Cannabis sativa L. J Biol Chem. 279:39767-74
    http://www.ncbi.nlm.nih.gov/pubmed/15190053
  • van Bakel H, Stout JM, Cote AG, Tallon CM, Sharpe AG, Hughes TR, Page JE. 2011. The draft genome and transcriptome of Cannabis sativa. Genome Biol.12: R102.
    http://genomebiology.com/2011/12/10/R102
  • Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. 2007. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 107: 785-96.
    http://www.ncbi.nlm.nih.gov/pubmed/18073554
  • Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet J-P. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182: E694-701.
    http://www.ncbi.nlm.nih.gov/pubmed/20805210
  • Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. 2013. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 14: 136-48.
    http://www.ncbi.nlm.nih.gov/pubmed/23237736